PT Kalbe Farma Tbk (ISX:KLBF) Cyclically Adjusted Revenue per Share: Rp0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:KLBF PT Kalbe Farma Tbk ISX:KLBF
77 GF Score
Price Rp790.00
GF Value Rp1,740.67
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is PT Kalbe Farma Tbk Cyclically Adjusted Revenue per Share?

PT Kalbe Farma Tbk ISX:KLBF 77 Cyclically Adjusted Revenue per Share is Rp0.00 as of Jun. 2026. GuruFocus rates ISX:KLBF with a GF Score™ of 77/100 and a GF Value™ of Rp1,740.67 (Significantly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

PT Kalbe Farma Tbk's adjusted revenue per share for the three months ended in Jun. 2026 was Rp216.575. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is Rp0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, PT Kalbe Farma Tbk's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of PT Kalbe Farma Tbk was 7.30% per year. The lowest was 6.10% per year. And the median was 6.55% per year.

As of today (2026-08-08), PT Kalbe Farma Tbk's current stock price is Rp790.00. PT Kalbe Farma Tbk's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was Rp0.00. PT Kalbe Farma Tbk's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PT Kalbe Farma Tbk was 4.48. The lowest was 1.08. And the median was 3.19.


PT Kalbe Farma Tbk  (ISX:KLBF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PT Kalbe Farma Tbk was 4.48. The lowest was 1.08. And the median was 3.19.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


PT Kalbe Farma Tbk Cyclically Adjusted Revenue per Share Related Terms


PT Kalbe Farma Tbk Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for PT Kalbe Farma Tbk's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Kalbe Farma Tbk Cyclically Adjusted Revenue per Share Chart

PT Kalbe Farma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 480.82 526.57 556.88 585.17 629.40

PT Kalbe Farma Tbk Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 605.88 615.65 629.40 643.79 0.00

ISX:KLBF vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Kalbe Farma Tbk Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PT Kalbe Farma Tbk's Cyclically Adjusted PS Ratio falls into.


ISX:KLBF
77GF Score
PT Kalbe Farma Tbk ISX:KLBF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Kalbe Farma Tbk Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PT Kalbe Farma Tbk's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=216.575/137.6954*137.6954
=216.575

Current CPI (Jun. 2026) = 137.6954.

PT Kalbe Farma Tbk Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 102.834 104.142 135.965
201612 106.625 105.222 139.532
201703 104.498 106.476 135.138
201706 110.249 107.722 140.926
201709 107.170 108.020 136.611
201712 108.634 109.017 137.212
201803 106.984 110.097 133.803
201806 114.466 111.085 141.887
201809 113.019 111.135 140.030
201812 115.114 112.430 140.983
201903 114.464 112.829 139.691
201906 124.014 114.730 148.838
201909 120.493 114.905 144.392
201912 123.875 115.486 147.698
202003 123.645 116.252 146.452
202006 123.917 116.630 146.299
202009 117.153 116.397 138.590
202012 128.359 117.318 150.654
202103 128.334 117.840 149.958
202106 135.580 118.184 157.963
202109 143.543 118.262 167.131
202112 152.807 119.516 176.050
202203 149.959 120.948 170.723
202206 147.475 123.322 164.663
202209 157.825 125.298 173.440
202212 166.647 126.098 181.974
202303 169.171 126.953 183.486
202306 157.145 127.663 169.494
202309 158.700 128.151 170.519
202312 170.533 129.395 181.473
202403 180.800 130.607 190.613
202406 171.373 130.792 180.419
202409 171.020 130.361 180.642
202412 182.562 131.432 191.263
202503 192.361 131.948 200.739
202506 182.471 133.241 188.572
202509 195.949 133.819 201.625
202512 205.156 135.271 208.833
202603 213.877 136.539 215.689
202606 216.575 137.695 216.575

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of Rp0.00 mean?
PT Kalbe Farma Tbk (ISX:KLBF) has a Cyclically Adjusted Revenue per Share of Rp0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PT Kalbe Farma Tbk and its competitors.
Is PT Kalbe Farma Tbk's Cyclically Adjusted Revenue per Share too high?
PT Kalbe Farma Tbk's current Cyclically Adjusted Revenue per Share is Rp0.00. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
PT Kalbe Farma Tbk's Cyclically Adjusted Revenue per Share of Rp0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PT Kalbe Farma Tbk and its competitors. PT Kalbe Farma Tbk's current Cyclically Adjusted Revenue per Share is Rp0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (ISX:KLBF) is currently considered Significantly Undervalued. The stock's GF Value™ is Rp1,740.67, compared to a current price of Rp790.00 — trading 54.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is Rp0.00. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For PT Kalbe Farma Tbk (ISX:KLBF), the current Cyclically Adjusted Revenue per Share is Rp0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Kalbe Farma Tbk (ISX:KLBF) Overvalued in 2026?

Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued. The current stock price of Rp790.00 is trading 54.6% below its estimated GF Value™ of Rp1,740.67. GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.

Key valuation signals for ISX:KLBF:

  • Cyclically Adjusted Revenue per Share: Rp0.00
  • GF Value™: Rp1,740.67 vs. price of Rp790.00 (54.6% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the ISX:KLBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Kalbe Farma Tbk Business Description

Address Jalan Let. Jend. Suprapto Kav. 4, Gedung KALBE, Cempaka Putih, P.O. Box 3105, Jakarta, IDN, 10510
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score

Get the complete analysis for ISX:KLBF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp790.00
Price
Rp1,740.67
GF Value